The OVA1 test assesses a patient’s risk of malignancy for an ovarian mass. This assessment is based on a combination of five biomarkers measured in a blood sample, producing a numerical score. A lower score indicates a lower risk of malignancy, while a higher score suggests a higher risk. For example, a score below a specified threshold might suggest a lower likelihood of cancer, directing a patient toward conservative management. Conversely, a score exceeding a defined threshold might warrant referral to a gynecologic oncologist for specialized surgical management.
This risk stratification tool aids clinicians in making informed decisions regarding the management of ovarian masses. It facilitates appropriate triage, helping ensure patients receive the right level of care at the right time. Historically, determining the potential malignancy of ovarian masses has been challenging. This multi-biomarker approach provides a more objective assessment than traditional methods, potentially improving outcomes and reducing unnecessary procedures for patients with benign masses.
